HMO Production
By expressing Serrazia mucinous MFS transporter in bacteria, HMO production cells are optimized, HMO efflux and by-product problems are solved, and the total yield and fermentation efficiency of HMO are improved.
Patent Information
- Application Number
- CN202180009967.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-01-23
- Filing Date
- 2021-01-22
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2041-01-22
AI Technical Summary
The prior art is difficult to accurately predict and identify aptamer transporters capable of effluenting recombinant production of human milk oligosaccharides (HMO), resulting in low HMO production efficiency and excessive by-products.
The MFS transporter heterologous gene introduced in Serratia marcescens, encodes amino acid sequences with at least 80% similarity to SEQ ID NO:1, expresses Marc protein to optimize HMO production cells, improves HMO efflux and yield, reduce by-products and biomass formation.
It significantly improves the total yield of HMO, reduces by-product formation and biomass generation, promotes the efficiency of the fermentation process and product recovery, and is particularly suitable for HMOs with tri- to tetrasaccharide structures such as 2'-FL, 3-FL, etc. Production.
Smart Images

Figure CN115003687B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of recombinant production of biomolecules in host cells. More specifically, it relates to a method for recombinant production of human milk oligosaccharides (HMOs) using genetically modified cells expressing proteins of the major facilitator superfamily (MFS). Background Art
[0002] Human milk oligosaccharides (HMOs) constitute the third largest solid component in human milk and are highly resistant to enzymatic hydrolysis. Therefore, a large part of HMOs are essentially not digested and absorbed, which allows them to enter the colon. In the colon, HMOs can serve as substrates to shape the intestinal ecosystem by selectively stimulating the growth of specific sugar-decomposing bacteria. This selectivity is considered to be beneficial for both infants and adults, as Bifidobacterium species are believed to have a positive impact on intestinal health (Chichlowski M. et al, (2012) J. Pediatr. Gastroenterol. Nutr. 5: 251-258; Elison E. et al., (2016) Brit J. Nutr, 116: 1356-1368).
[0003] In addition to their prebiotic properties, HMOs are also associated with other positive effects, which expand their application areas (Kunz C. et al., (2014) Food Oligosaccharides: Production, Analysis and Bioactivity, 1st Edition, p5-20, Eds. Moreno J. and Luz Sanz M., John Wiley & Sons, Ltd).
[0004] The obvious health benefits of HMOs enable them to be approved for use in foods, such as infant formula and foods, as well as for consumer health products. The biological production of HMOs is a valuable, cost-effective way to manufacture HMOs on a large scale. It relies on genetically engineered bacteria that are constructed to express the glycosyltransferases required to synthesize the desired oligosaccharides and utilize the inherent nucleotide sugar pool of bacteria as HMO precursors. Recent developments in HMO bioproduction technology have made it possible to overcome certain inherent limitations of bacterial expression systems. For example, bacterial cells that produce HMOs can be genetically modified to increase the limited intracellular nucleotide sugar pool in bacteria (WO2012112777), thereby increasing the activity of enzymes involved in HMO production (WO2016040531), or promoting the secretion of synthesized HMOs into the extracellular medium (WO2010142305, WO2017042382). In addition, the expression of the gene of interest in the recombinant cell can be regulated by using a specific promoter or other gene expression regulator, for example, as recently described in WO2019123324.
[0005] The methods described in WO2010142305 and WO2017042382 have the following advantages: it can reduce the metabolic burden on the production cells by high levels of recombinant gene expression, for example using the methods of WO2012112777, WO2016040531 or WO2019123324. This approach has attracted increasing attention in the engineering of recombinant HMO production cells, for example, several new sugar transporter gene encoding proteins and fermentation methods have been recently described, which can promote the efflux of recombinantly produced 2'-fucosyllactose (2'-FL), which is the most abundant HMO in human milk (WO2018077892, US201900323053, US201900323052). However, currently, there is no algorithm that can accurately find suitable transporters capable of efflux of different recombinantly produced HMO structures among the numerous bacterial proteins with predicted transporter functions in multiple protein databases (e.g., UniProt), because the structures / factors that determine the substrate specificity of sugar transporters are still not well studied and remain highly unpredictable. Summary of the invention
[0006] Identification of new and efficient sugar efflux transporters specific for different recombinantly produced HMOs and development of recombinant cells expressing said proteins would be advantageous for large-scale industrial HMO production.
[0007] The present invention provides a recombinant cell capable of producing human milk oligosaccharides (HMOs), wherein the cell expresses a heterologous gene encoding a putative MFS (major facilitating superfamily) transporter derived from the bacterium Serratia marcescens. More specifically, the present invention relates to a genetically modified cell optimized for the production of oligosaccharides, in particular HMOs, comprising a recombinant nucleic acid encoding a protein having at least 80% sequence similarity to the amino acid sequence SEQ ID NO: 1 ( Figure 3 ). The amino acid sequence referred to herein as SEQ ID NO: 1 refers to an amino acid sequence that has 100% identity to the amino acid sequence of GenBank Accession No. WP_060448169.1. The MFS transporter having the amino acid sequence SEQ ID NO: 1 is interchangeably referred to herein as "Marc protein" or "Marc transporter" or "marc"; the nucleic acid sequence encoding the marc protein is referred to herein as "Marc encoding nucleic acid / DNA" or "marc gene" or "marc".
[0008] The present invention demonstrates that the use of HMO producing recombinant cells expressing the Marc protein results in very significant improvements in the HMO manufacturing process both in relation to HMO fermentation and purification. The recombinant cells and HMO production methods disclosed herein provide higher yields of total HMO production, lower byproduct formation or byproduct to product ratio, lower biomass formation per fermentation, and facilitate recovery of the fermentation broth during downstream processing. Surprisingly, it was found that expression of the DNA sequence encoding Marc in different HMO producing cells was associated with the accumulation of some specific HMOs in the extracellular medium as well as other HMOs inside the producing cells, and was associated with an increase in the total HMO production. Surprisingly, the study found that the increased efflux of the produced HMOs was specific for HMOs composed of three or four unit monosaccharides (i.e., they were trisaccharides and tetrasaccharides), such as 2'-fucosyllactose (2'-FL), 3-fucosyllactose (3-FL), 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), lacto-N-triose-2 (LNT-2), lacto-N-neotetraose (LNnT) and lacto-N-tetraose (LNT), but not for larger oligosaccharide structures such as pentasaccharides and hexasaccharides that accumulate inside the production cells. Surprisingly, the study also found that in the corresponding HMO production cells expressing the marc gene, the total production of major HMOs such as 2'-fucosyllactose (2'-FL), 3'-fucosyllactose (3-FL), lacto-N-triose (LNT II) and lacto-N-tetraose (LNT) was also increased, while in these cells, correspondingly, the production of byproducts such as difucosyllactose (DFL), lacto-N-fucopentaose V (LNFP V) or p-lacto-neo-hexaose-I (pLNH-I) was often reduced, and the byproduct oligosaccharides usually accumulated inside the production cells. In addition, it is very unexpected that the expression of the Marc protein in HMO production cells leads to a reduction in the formation of biomass during fermentation and to a healthier cell culture, as reflected by the reduced number of dead cells at the end of the fermentation, which makes the manufacturing process more efficient because more products are produced per biomass unit.
[0009] Thus, a first aspect of the present invention relates to a genetically modified cell capable of producing one or more HMOs, wherein the cell comprises a recombinant nucleic acid encoding the protein of SEQ ID NO: 1 or a functional homologue thereof, the amino acid sequence of which is at least 80% identical, preferably at least 85% identical, more preferably at least 90% identical to the sequence of SEQ ID NO: 1.
[0010] A second aspect of the present invention relates to a nucleic acid construct comprising a nucleic acid sequence encoding an MFS transporter, wherein the nucleic acid sequence encoding the protein has at least 70% sequence identity with SEQ ID NO: 2, such as at least 80%, such as at least 85%, such as at least 95%, such as at least 99%, and a genetically modified cell comprising the above-mentioned nucleic acid construct, which is Escherichia coli.
[0011] In one aspect, the nucleic acid construct comprises a nucleic acid sequence encoding a MFS transporter, wherein the nucleic acid sequence has at least 70% identity to SEQ ID NO:2.
[0012] A third aspect of the present invention relates to a method for producing one or more oligosaccharides, the method comprising the steps of:
[0013] (i) providing a genetically modified cell capable of producing HMO, wherein the cell comprises a recombinant nucleic acid encoding a protein of SEQ ID NO: 1 or a functional homologue thereof, the amino acid sequence of the functional homologue being at least 80% identical to SEQ ID NO: 1, preferably at least 85% identical, more preferably at least 90% identical;
[0014] (ii) culturing the cell according to (i) in a suitable cell culture medium to express the recombinant nucleic acid;
[0015] (iii) harvesting the one or more HMOs produced in step (ii).
[0016] The present invention also relates to the use of a genetically modified cell or a nucleic acid construct comprising a heterologous nucleic acid sequence encoding a major facilitator superfamily (MFS) protein for producing one or more human milk oligosaccharides (HMOs), wherein the nucleic acid sequence has at least 70% sequence identity with SEQ ID NO: 2.
[0017] As described above, in the process of culturing a genetically modified cell capable of producing one or more HMOs, the cell comprising a nucleic acid encoding a Marc transporter, it was surprisingly found that the corresponding one or more HMOs were produced in high yields with reduced formation of byproducts and biomass. This facilitates the recovery of the HMOs in downstream processing, for example, the overall recovery and purification process can include fewer steps and the overall purification time can be shortened.
[0018] These effects of increasing product yield and facilitating product recovery make the present invention superior to the disclosures of the prior art.
[0019] Further aspects and advantageous features of the present invention are described in detail and illustrated by the following non-limiting examples. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] Figure 1 The interior and exterior of engineered E. coli cells with and without overexpression of the MFS transporter of SEQ ID NO: 1 are shown ( Figure 1 )'s relative distribution of 3-FL.
[0021] FIG. 2 shows the relative distribution of 2'-FL inside and outside the cell in engineered E. coli with and without overexpression of the MFS transporter of SEQ ID NO: 1 ( Figure 2A ), and relative cell optical density measured at 600 nm ( Figure 2B ).
[0022] Figure 3 SEQ ID NO: 1 is shown. DETAILED DESCRIPTION
[0023] In the following, embodiments of the present invention will be described in more detail. Unless otherwise explicitly stated, each specific feature change can be applied to other embodiments of the present invention.
[0024] In general, unless otherwise explicitly defined or indicated, all terms used in the present invention are to be interpreted according to their ordinary meaning in the technical field and are applicable to all aspects and embodiments of the present invention. Unless otherwise explicitly indicated, all references to "a / an / the [cell, sequence, gene, transporter, step, etc.]" are to be interpreted openly as referring to at least one instance of the cell, sequence, gene, transporter, step, etc. Unless explicitly indicated, the steps of any method disclosed herein do not have to be performed in the exact order disclosed.
[0025] The present invention generally relates to a genetically modified cell for the efficient production of oligosaccharides, and the use of the genetically modified cell in an oligosaccharide production method. In particular, the present invention relates to a genetically modified cell capable of synthesizing oligosaccharides, preferably heterologous oligosaccharides, in particular human milk oligosaccharides (HMOs). Therefore, the cell of the present invention is modified to express a set of recombinant nucleic acids necessary for the cell to synthesize one or more HMOs (which enables the cell to synthesize one or more HMOs), such as genes encoding one or more enzymes having glycosyltransferase activity as described below. The oligo-producing recombinant cell of the present invention is further modified to include a heterologous recombinant nucleic acid sequence, preferably a DNA sequence encoding a putative MFS (major facilitator superfamily) transporter derived from the bacterium Serratia marcescens. More specifically, the present invention relates to a genetically modified cell optimized for the production of one or more specific oligosaccharides, in particular one or more specific HMOs, comprising a gene encoding a polypeptide having the same amino acid sequence as SEQ ID NO:1 ( Figure 3) has at least 80% sequence similarity, preferably at least 85%, more preferably at least 90%, and even more preferably at least 95% sequence similarity. The amino acid sequence referred to herein as SEQ ID NO: 1 is an amino acid sequence that has 100% identity with the amino acid of GenBank Accession No. WP_060448169.1.
[0026] Thus, a first aspect of the present invention relates to a genetically modified cell capable of producing one or more HMOs, wherein the cell comprises a recombinant nucleic acid encoding a protein of SEQ ID NO: 1 or a functional homologue thereof, the amino acid sequence of which is at least 80% identical, preferably at least 85% identical, more preferably at least 90% identical to SEQ ID NO: 1. In the present invention, the term "functional homologue" refers to a protein having an amino acid sequence identity of 80% to 99.9% with SEQ ID NO: 1 and having a function that is beneficial to achieving at least one beneficial effect of the present invention, such as increasing the total HMO production of the host cell, facilitating the recovery of the produced HMOs, improving the HMO production efficiency and / or the viability of the HMO producing cells.
[0027] The MFS transporter having the amino acid sequence SEQ ID NO: 1 is referred to interchangeably herein as “Marc protein” or “Marc transporter” or “Marc”; for purposes of the present invention, the nucleic acid sequence encoding the Marc protein is referred to herein as “Marc encoding nucleic acid / DNA” or “marc gene” or “marc”.
[0028] The term "major facilitator superfamily (MFS)" refers to a large and unusually diverse family of secondary active transporters that are responsible for transporting a range of different substrates, including sugars, drugs, hydrophobic molecules, peptides, organic ions, etc. The specificity of sugar transporters is highly unpredictable, and the identification of novel transporters that are specific for, for example, oligosaccharides requires unburdened laboratory experiments (for more details, see review Reddy V Set al. (2012), FEBS J. 279 (11): 2022-2035). In the present invention, the term "MFS transporter" refers to a protein that facilitates the transport of oligosaccharides, preferably HMOs, across cell membranes, preferably a protein that facilitates the transport of HMOs / oligosaccharides synthesized by host cells from the cytosol to the cell culture medium, preferably HMOs / oligosaccharides comprising three or four sugar units, in particular 2'-FL, 3-FL, LNT-2, LNT, LNnT, 3'-SL or 6'-SL. Additionally, or alternatively, MFS transporters may also facilitate the efflux of molecules that are not considered to be HMOs or oligosaccharides according to the present invention, such as lactose, glucose, cellular metabolites or toxins.
[0029] In the context of two or more nucleic acid or amino acid sequences, the term "[a certain value]% sequence identity" means that, over a comparison window or a specified nucleic acid or amino acid sequence, when the comparison and alignment are maximized in correspondence, the two or more sequences have a given percentage of common nucleotides or amino acid residues (i.e., the sequences have at least 90% identity). The percentage identity of nucleic acid or amino acid sequences can be measured using the BLAST 2.0 sequence comparison algorithm with default parameters, or by manual alignment and visual inspection (see, e.g., http: / / www.ncbi.nlm.nih.gov / BLAST / ). This definition also applies to the complement of the test sequence and sequences with deletions and / or additions, as well as sequences with substitutions. An example of an algorithm suitable for determining percentage identity, sequence similarity and for alignment is the BLAST 2.2.20+ algorithm, which is disclosed in Altschul et al. Nucl. Acids Res. 25, 3389 (1997). BLAST 2.2.20+ is used to determine the percentage sequence identity of nucleic acids and proteins of the present invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (http: / / www.ncbi.nlm.nih.gov / ). Examples of commonly used sequence alignment algorithms are
[0030] CLUSTAL Omega(http: / / www.ebi.ac.uk / Tools / msa / clustalo / ),
[0031] EMBOSS Needle(http: / / www.ebi.ac.uk / Tools / psa / emboss_needle / ),
[0032] MAFFT(http: / / mafft.cbrc.jp / alignment / server / ), or
[0033] MUSCLE (http: / / www.ebi.ac.uk / Tools / msa / muscle / ).
[0034] In the context of the present invention, the term "oligosaccharide" refers to a sugar polymer containing several monosaccharide units. In some embodiments, the preferred oligosaccharide is a sugar polymer composed of three or four monosaccharide units, i.e. a trisaccharide or a tetrasaccharide. The preferred oligosaccharide of the present invention is human milk oligosaccharide (HMO).
[0035] In the present invention, the term "human milk oligosaccharide" or "HMO" refers to a complex carbohydrate present in human breast milk (for reference, see Urashima et al. Milk Oligosaccharides. Nova Science Publisher (2011); or Chen, Adv. Carbohydr. Chem. Biochem. 72, 113 (2015)). HMO has a core structure including a lactose unit at the reducing end, which may be extended by one or more β-N-acetyl-lactosaminyl and / or one or more β-lacto-N-biosyl units, and the core structure may be substituted by α-L-fucopyranosyl and / or α-N-acetyl-neuraminic acid (sialyl) moieties. In this regard, non-acidic (or neutral) HMOs do not contain sialic acid residues, while acidic HMOs have at least one sialic acid residue in their structure. Non-acidic (or neutral) HMOs can be fucosylated or non-fucosylated. Examples of such neutral non-fucosylated HMOs include lacto-N-triose 2 (LNT-2), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), lacto-N-neohexaose (LNnH), p-lacto-N-neohexaose (pLNnH), p-lacto-N-hexaose (pLNH), and lacto-N-hexaose (LNH). Examples of neutral fucosylated HMOs include 2'-fucosyllactose (2'-FL), lacto-N-fucopentaose I (LNFP-I), lacto-N-difucohexaose I (LNDFH-I), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose II (LNFP-II), lacto-N-fucopentaose III (LNFP-III), lacto-N-difucohexaose III (LNDFH-I ... III), fucosyl-lacto-N-hexaose II (FLNH-II), lacto-N-fucopentaose V (LNFP-V), lacto-N-difucohexaose II (LNDFH-II), fucosyl-lacto-N-hexaose I (FLNH-I), fucosyl-p-lacto-N-hexaose I (FpLNH-I), fucosyl-p-lacto-N-neohexaose II (FpLNnHII) and fucosyl-lacto-N-neohexaose (FLNnH).Examples of acidic HMOs include 3'-sialyllactose (3'-SL), 6'-sialyllactose (6'-SL), 3-fucosyl-3'-sialyllactose (FSL), 3'-O-sialyllacto-N-tetraose a (LST a), fucosyl-LST a (FLST a), 6'-O-sialyllacto-N-tetraose b (LST b), fucosyl-LST b (FLST b), 6'-O-sialyllacto-N-tetraose (LST c), fucosyl-LST c (FLST c), 3'-O-sialyllacto-N-neotetraose (LST d), fucosyl-LST d (FLST d). d), sialyl-lacto-N-hexaose (SLNH), sialyl-lacto-N-neohexose I (SLNH-I), sialyl-lacto-N-neohexose II (SLNH-II) and disialyl-lacto-N-tetraose (DSLNT). In the context of the present invention, lactose is not considered as a sub-species of HMO.
[0036] In some embodiments of the present invention, tri-HMO and tetra-HMO may be preferred, for example, the trisaccharides 2'-FL, 3-FL, LNT-2, 3'-SL, 6'-SL, and the tetrasaccharides DFL, LNT, LNnT, FSL.
[0037] In order to be able to synthesize one or more HMOs, the recombinant cells of the present invention include at least one recombinant nucleic acid encoding a functional enzyme with glycosyltransferase activity. The galactosyltransferase gene can be integrated into the genome of the host cell (via chromosomal integration), or alternatively, it can be included in plasmid DNA and expressed in a plasmid-borne form. If more than two glycosyltransferases are required for the production of HMOs, such as LNT or LNnT, two or more recombinant nucleic acids encoding different enzymes with glycosyltransferase activity can be integrated into the genome and / or expressed from a plasmid, for example, β-1,3-N-acetylglucosaminyltransferase (a first recombinant nucleic acid encoding a first glycosyltransferase) is combined with β-1,3-galactosyltransferase (a second recombinant nucleic acid encoding a second glycosyltransferase) for the production of LNT, wherein the first and second recombinant nucleic acids can be chromosomally integrated or integrated on a plasmid independently of each other. In a preferred embodiment, both the first and second recombinant nucleic acids are stably integrated into the chromosome of the production cell; in another embodiment, at least one of the first and second glycosyltransferases is plasmid-borne. The protein / enzyme with glycosyltransferase activity (glycosyltransferase) can be selected from enzymes with the following enzyme activities in different embodiments: α-1,2-fucosyltransferase, α-1,3-fucosyltransferase, α-1,3 / 4-fucosyltransferase, α-1,4-fucosyltransferase, α-2,3-sialyltransferase, α-2,6-sialyltransferase, β-1,3-N-acetylglucosaminyltransferase, β-1,6-N-acetylglucosaminyltransferase, β-1,3-galactosyltransferase and β-1,4-galactosyltransferase. For example, the production of 2'-FL requires the modified cell to express active α-1,2-fucosyltransferase; to produce 3-FL, the modified cell needs to express active α-1,3-fucosyltransferase; to produce LNT, the modified cell needs to express at least two glycosyltransferases, β-1,3-N-acetylglucosaminyltransferase and β-1,3-galactosyltransferase; to produce 6'-SL, the modified cell needs to express active α-2,6-sialyltransferase. Some non-limiting embodiments of proteins having glycosyltransferase activity, which can be encoded by a recombinant gene included in the production cell, can be selected from the non-limiting examples in Table 1.
[0038] Table 1
[0039]
[0040]
[0041]
[0042] On the one hand, the present invention provides a nucleic acid construct, which includes a heterologous nucleic acid sequence encoding a protein capable of sugar transport, wherein the above protein is a major facilitator superfamily (MFS) protein as shown in SEQ ID NO: 1, or a functional homolog thereof whose amino acid sequence has at least 80% identity with SEQ ID NO: 1, wherein the nucleic acid sequence encoding the MFS protein has at least 70% sequence identity with the SEQ ID NO: 2 sequence.
[0043] The terms "heterologous nucleic acid sequence", "recombinant gene / nucleic acid / DNA coding" or "coding nucleic acid sequence" refer to an artificial nucleic acid sequence (i.e., produced in vitro using standard laboratory methods for producing nucleic acid sequences) that contains a set of consecutive, non-overlapping triplets (codons) that are transcribed into mRNA and translated into a polypeptide when under the control of appropriate control sequences (i.e., promoters). The boundaries of the coding sequence are generally determined by the ribosome binding site, the transcription start codon (AUG, GUG or UUG), and the translation stop codon (UAA, UGA or UAG) located just upstream of the 5' end of the open reading frame of the mRNA. Coding sequences may include, but are not limited to, genomic DNA, cDNA, synthetic and recombinant nucleic acid sequences. The term "nucleic acid" includes RNA, DNA and cDNA molecules. It is understood that due to the degeneracy of the genetic code, many nucleotide sequences encoding a given protein can be generated. The term nucleic acid is used interchangeably with the term "polynucleotide". "Oligonucleotides" are short-chain nucleic acid molecules. A "primer" is an oligonucleotide that can act as a starting point for synthesis under conditions that induce the synthesis of a primer extension product complementary to a nucleic acid chain (i.e., in the presence of nucleotides and an inducing agent such as a DNA polymerase, and at a suitable temperature and pH), whether it is naturally occurring, such as in a purified restriction digest, or synthetically produced. Primers are preferably single-stranded to achieve maximum efficiency in amplification, but may alternatively be double-stranded. If double-stranded, the primers are first treated to separate their chains before being used to prepare extension products. Preferably, primers are deoxyribonucleotides. The primers must be long enough to initiate the synthesis of extension products in the presence of an inducing agent. The exact length of the primer depends on many factors, including temperature, primer source, and the purpose of the method.
[0044] The recombinant nucleic acid sequence of the present invention can be a coding DNA sequence, such as a gene, or a non-coding DNA sequence, such as a regulatory DNA, such as a promoter sequence. In one aspect, the present invention relates to providing a recombinant cell comprising a recombinant DNA sequence encoding an enzyme necessary for producing one or more HMOs and a DNA sequence encoding a Marc protein. Therefore, in one embodiment, the present invention relates to a nucleic acid construct comprising a coding nucleic acid sequence, i.e., a recombinant DNA sequence of a gene of interest, such as a glycosyltransferase gene or a marc gene, and a non-coding DNA sequence, such as a promoter DNA sequence, such as a recombinant promoter sequence derived from a promoter of a lac operon or a glp operon, or a promoter sequence derived from another genomic promoter DNA sequence, or a synthetic promoter sequence, wherein the coding sequence and the promoter sequence are operably linked. The term "operably linked" refers to a functional relationship between two or more nucleic acid (e.g., DNA) fragments. Generally, it refers to a functional relationship between a transcriptional regulatory sequence and a transcribed sequence. For example, if a promoter sequence stimulates or regulates the transcription of a coding sequence in a suitable host cell or other expression system, it is operably linked to a coding sequence. Generally, promoter transcriptional regulatory sequences that are operably linked to a transcribed sequence are physically contiguous to the transcribed sequence, ie, they are cis-acting.
[0045] In one embodiment, the nucleic acid construct of the present invention may be part of a vector DNA, in another embodiment, the construct is an expression component / cassette that is integrated into the host cell genome. Thus, the term "nucleic acid construct" refers to an artificially constructed nucleic acid fragment, particularly a DNA fragment, that is intended to be "transplanted" into a target cell, such as a bacterial cell, to modify the gene expression of the genome, or to express a gene / coding DNA sequence that may be included in the construct. In the context of the present invention, a nucleic acid construct comprises a recombinant DNA sequence that comprises two or more recombinant DNA sequences: essentially, a non-coding DNA sequence comprising a promoter DNA sequence, and a coding DNA sequence encoding a glycosyltransferase of a gene of interest, such as a Marc protein, another gene for producing HMOs in a host cell. Preferably, the construct further comprises a non-coding DNA sequence that regulates the transcription or translation of the coding DNA of the construct, such as a DNA sequence that promotes the binding of ribosomes to the transcription product, a leader DNA sequence that stabilizes the transcription product.
[0046] Integration of the recombinant gene of interest included in the construct (expression component) into the bacterial genome can be achieved by conventional methods, for example, by using a linear cassette containing flanking sequences homologous to a specific site on the chromosome, as described for the attTn7-site (Waddell CS and Craig NL, Genes Dev. (1988) Feb; 2(2): 137-49.); methods for genomic integration of nucleic acid sequences, wherein recombination is mediated by the Red recombinase function of bacteriophage λ or the RecE / RecT recombinase function of the Rac prophage (Murphy, J Bacteriol. _ (1998); 180(8): 2063-7; Zhang et al., Nature Genetics (1998) 20: 123-128; Muyrers et al., EMBO Rep. (2000) 1(3): 239-243); methods based on Red / ET recombination (Wenzel et al., Chem Biol. (2005), 12(3):349-56.; Vetcher et al., Appl Environ Microbiol. (2005); 71(4):1829-35); or positive clones, ie clones carrying the expression component, can be selected by, for example, marker genes, or loss or gain of gene function.
[0047] A single copy of the expression module comprising the gene of interest may be sufficient to ensure the production of the desired HMO and achieve the desired effect according to the present invention. Thus, in some preferred embodiments, the present invention relates to a recombinant HMO producing cell comprising one, two or three copies of the gene of interest integrated in the genomic DNA of the cell. In some embodiments, a single copy of the gene is preferred.
[0048] In a preferred embodiment, the recombinant encoding nucleic acid sequence of the nucleic acid construct of the present invention is heterologous with respect to the promoter, which means that the equivalent native coding sequence in the genome of the species from which it is derived is transcribed under the control of another promoter sequence (i.e., not the promoter sequence of the construct). In addition, for the host cell, the encoding DNA can be heterologous (i.e., derived from another biological species or genus), for example, a DNA sequence encoding a Marc protein expressed in an E. coli host cell, or homologous (i.e., derived from a host cell), such as a gene of the colic acid operon, the wca gene.
[0049] The term "regulatory element" or "promoter" or "promoter region" or "promoter element" is a nucleic acid sequence that is recognized and bound by a DNA-dependent RNA polymerase during the initiation of transcription. The promoter, together with other transcriptional and translational regulatory nucleic acid sequences (also referred to as "control sequences"), is necessary for the expression of a given gene or a group of genes (operon). In general, transcriptional and translational regulatory sequences include, but are not limited to, promoter sequences, ribosome binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancers or activation sequences. "Transcription start site" refers to the first nucleotide to be transcribed, which is designated as +1. The nucleotides downstream of the start site are numbered +2, +3, +4, etc., and the nucleotides in the 5' opposite (upstream) direction are numbered -1, -2, -3, etc. The promoter DNA sequence of the construct can be derived from the promoter region of any gene in the genome of the selected species, preferably, the promoter region of the Escherichia coli genomic DNA. Therefore, any promoter DNA sequence that can bind to RNA polymerase and initiate transcription is suitable for practicing the present invention. In principle, any promoter DNA sequence can be used to control the transcription of the recombinant gene of interest of the construct, and different or identical promoter sequences can be used to drive the transcription of different genes of interest integrated into the host cell genome or in the expression vector DNA. In order to optimally express the recombinant gene included in the construct, the construct may include further regulatory sequences, such as: a leading DNA sequence, such as a DNA sequence of the 5'-untranslated region (5'UTR) of the glp gene derived from Escherichia coli, a ribosome binding sequence. Examples of the sequences below are described in WO2019123324 (incorporated herein as a reference), and are illustrated in the non-limiting working examples of the present invention.
[0050] In some preferred embodiments, the regulatory element for regulating the expression of the recombinant gene included in the construct of the present invention is the glpFKX operator promoter PglpF, and in other preferred embodiments, the promoter is the lac operator promoter Plac.
[0051] On the other hand, the regulatory element for regulating the expression of the recombinant gene included in the construct of the present invention is mgIBAC; the galactose / methyl-galactoside transporter promoter PmgIB or its variants, such as but not limited to PmglB_70UTR of SEQ ID NO:12, or PmglB_70UTR_SD4 of SEQ ID NO:13.
[0052] In another aspect, the regulatory element for regulating recombinant gene expression included in the construct of the present invention is gatYZABCD; tagatose-1,6-bisP aldolase promoter PgatY or a variant thereof, such as but not limited to PgatY_U70UTR of SEQ ID NO:14.
[0053] The preferred regulatory elements present in the genetically modified cells or nucleic acid constructs of the present invention are selected from PgatY_70UTR, PglpF, PglpF_SD1, PglpF_SD10, PglpF_SD2, PglpF_SD3, PglpF_SD4, PglpF_SD5, PglpF_SD6, PglpF_SD7, PglpF_SD8, PglpF_SD9, Plac_16UTR, Plac, PmglB_70UTR and PmglB_70UTR_SD4.
[0054] Particularly preferred regulatory elements present in the genetically modified cell or in the nucleic acid construct of the invention are selected from the group consisting of PglpF and Plac.
[0055] However, any promoter is suitable for practicing the present invention as long as it is capable of transcribing and / or regulating the transcription level of one or more recombinant nucleic acids (or one or more regulatory nucleic acids) encoding one or more proteins that are necessary or beneficial for achieving optimal levels of biosynthetic production of one or more HMOs in a host cell, and allows for the desired effects according to the present invention to be achieved, such as proteins involved in the transmembrane transport of HMOs or HMO precursors, degradation of HMO production by-products, gene expression regulatory proteins, etc.
[0056] Preferably, the construct of the present invention, including genes related to HMO biosynthesis production, promoter DNA sequences and other regulatory sequences such as ribosome binding site sequences (e.g., Shine-Dalgarno sequences), expressed in a host cell, is capable of producing HMOs at a level of at least 0.03 g / OD (optical density) in 1 liter of fermentation medium including the host cell suspension, for example, about 0.05 g / l / OD to about 0.1 g / l / OD. For the purposes of the present invention, the latter level of HMO production is considered "sufficient", and host cells capable of producing the desired HMOs at this level are considered "suitable host cells", i.e., the cells can be further modified to express an HMO transporter, such as Marc, to achieve at least one effect beneficial to HMO production as described herein.
[0057] The genetically modified cells or nucleic acid constructs of the present invention comprise a nucleic acid sequence, such as a heterologous gene encoding a putative MFS (major facilitator superfamily) transporter.
[0058] The MFS transporter of particular interest in the present invention is the Marc protein. Thus, the nucleic acid construct of the present invention contains a nucleic acid sequence having at least 70% sequence identity with the gene marc SEQ ID NO:2.
[0059] The nucleic acid sequence contained in the genetically modified cell or in the nucleic acid construct encodes the protein of SEQ ID NO: 1, or a functional homologue having an amino acid sequence at least 80% identical to SEQ ID NO: 1.
[0060] Functional homologues of the protein of SEQ ID NO: 1 can be obtained by mutagenesis. Compared with the functionality of the amino acid sequence SEQ ID NO: 1, the functional homologue should have at least 50% retained functionality, such as 60%, 70%, 80%, 90% or 100%. Compared with the functionality of the amino acid sequence SEQ ID NO: 1, the functional homologue may have a higher functionality. The functional homologue of SEQ ID NO: 1 should be able to increase the HMO production of the genetically modified cells according to the invention.
[0061] The genetically modified cells (host cells or recombinant cells) can be, for example, bacteria or yeast cells. In a preferred embodiment, they can be genetically modified bacterial cells. For bacterial host cells, there are no restrictions in principle; they can be true bacteria (Gram-positive or Gram-negative) or archaea, as long as they allow the insertion of genetic modifications of the genes of interest and can be cultured on a production scale. Preferably, the host cells have properties that allow cultivation to high cell densities. Non-limiting examples of bacterial host cells suitable for recombinant industrial production of HMOs according to the present invention can be Erwinia herbicola (Pantoea agglomerans), Citrobacter freundii, Pantoea citrea, Pectobacterium carotovorum or Xanthomonas campestris. Bacillus bacteria may also be used, including Bacillus subtilis, Bacillus licheniformis, Bacillus coagulans, Bacillus thermophilus, Bacillus laterosporus, Bacillus megaterium, Bacillus mycoides, Bacillus pumilus, Bacillus lentus, Bacillus cereus, and Bacillus circulans.Similarly, bacteria of the genera Lactobacillus and Lactococcus can be modified using the methods of the invention, including, but not limited to, Lactobacillus acidophilus, Lactobacillus salivarius, Lactobacillus plantarum, Lactobacillus helveticus, Lactobacillus delbrueckii, Lactobacillus rhamnosus, Lactobacillus bulgaricus, Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus casei, Lactobacillus reuteri, Lactobacillus jensenii, and Lactococcus lactis. Streptococcus thermophiles and Proprionibacterium freudenreichii are also bacterial species suitable for use in the present invention. Also included as part of the present invention are strains modified as described herein from the genera Enterococcus (e.g., Enterococcus faecium and Enterococcus thermophiles), Bifidobacterium (e.g., Bifidobacterium longum, Bifidobacterium infantis, and Bifidobacterium bifidum), Sporolactobacillus spp., Micromomospora spp., Micrococcus spp., Rhodococcus spp., and Pseudomonas (e.g., Pseudomonas fluorescens and Pseudomonas aeruginosa).The bacteria comprising the features of the present invention are cultured in the presence of lactose, and the oligosaccharides, such as HMOs, produced by the cells are recovered from the bacteria themselves or from the supernatant of the bacterial culture. In a preferred embodiment, the genetically modified cells of the present invention are E. coli cells.
[0062] In another preferred embodiment, the host cell is a yeast cell, such as Saccharomyces cerevisiae, Schizosaccharomyces pombe, Pichia pastoris, Kluveromyces lactis, Kluveromyces marxianus, and the like.
[0063] The HMO produced by the recombinant cells of the present invention can be purified using appropriate methods available in the art (for example, as described in WO2015188834, WO2017182965 or WO2017152918).
[0064] The genetically modified cells of the present invention can be provided using standard methods in the art, such as those described in the manuals of Sambrook et al. Wilson & Walker, Maniatise et al., and Ausubel et al.
[0065] Host cells suitable for HMO production, such as E. coli, can include an endogenous β-galactosidase gene or an exogenous β-galactosidase gene, for example, E. coli includes an endogenous lacZ gene (e.g., GenBank Accession No. V00296 (GI:41901)). For the purposes of the present invention, the HMO producing cell gene is manipulated to include any β-galactosidase gene or to include an inactivated gene. The gene can be inactivated by completely or partially deleting the corresponding nucleic acid sequence from the bacterial genome, or the gene sequence is mutated during transcription, or, if transcribed, the transcript is not translated, or if translated into a protein (i.e., β-galactosidase), the protein does not have the corresponding enzyme activity. In this way, the HMO producing bacteria accumulate an increased intracellular lactose pool, which is beneficial for the production of HMOs.
[0066] In some embodiments, engineered cells, such as bacteria, contain defective sialic acid decomposition pathways. "Sialic acid decomposition pathways" refers to a series of reactions, usually controlled and catalyzed by enzymes, resulting in sialic acid degradation. An exemplary sialic acid decomposition pathway of the present invention is an Escherichia coli pathway. In this pathway, sialic acid (Neu5Ac; N-acetylneuraminic acid) is degraded by enzymes NanA (N-acetylneuraminic acid lyase) and NanK (N-acetylmannosamine kinase) and NanE (N-acetylmannosamine-6-phosphate epimerase), which are all encoded by the nanATEK-yhcH operon and repressed by NanR (http: / / ecocyc.org / ECOLI). By introducing mutations in endogenous nanA (N-acetylneuraminic acid lyase) (e.g., GenBank Accession No. D00067.1 (GL216588)) and / or nanK (N-acetylmannosamine kinase) genes (e.g., GenBank Accession No. (amino acid) BAE77265.1 (GL85676015)) and / or nanE (N-acetylmannosamine-6-phosphate epimerase, GI:947745, incorporated herein by reference), a defective sialic acid catabolic pathway is presented in an E. coli host. Optionally, the nanT (N-acetylneuraminic acid transporter) gene is also inactivated or mutated. Other intermediates of sialic acid metabolism include: (ManNAc-6-P) N-acetylmannosamine-6-phosphate; (GlcNAc-6-P) N-acetylglucosamine-6-phosphate; (GlcN-6-P) glucosamine-6-phosphate and (Fruc-6-P) fructose-6-phosphate. In some preferred embodiments, nanA is mutated. In other preferred embodiments, nanA and nanK are mutated, while nanE remains functional. In another preferred embodiment, nanA and nanE are mutated, while nanK is not mutated, inactivated or deleted. Mutations are one or more changes in the nucleic acid sequence encoding the gene product of nanA, nanK, nanE and / or nanT. For example, mutations can be 1, 2, up to 5, up to 10, up to 25, up to 50 or up to 100 changes in the nucleic acid sequence. For example, nanA, nanK, nanE and / or nanT genes are mutated by invalid mutations. Null mutations described herein include amino acid substitutions, additions, deletions or insertions, which result in enzyme loss of function (i.e., reduced or no activity) or enzyme loss (i.e., no gene product). "Delete" refers to a coding region that is completely or partially removed, thereby not producing a (functional) gene product.Inactivation means that the coding sequence has been altered so that the resulting gene product is functionally inactive or the encoded gene product has an activity less than 100%, such as 90%, 80%, 70%, 60%, 50%, 40%, 30% or 20% of the activity of the native, naturally occurring, endogenous gene product. A "non-mutated" gene or protein does not differ from the native, naturally occurring or endogenous coding sequence by 1, 2, up to 5, up to 10, up to 20, up to 50, up to 100, up to 200 or up to 500 or more codons, or does not differ from the corresponding encoded amino acid sequence.
[0067] In addition, the host cell (e.g., E. coli) also includes sialic acid synthesis capability. For example, by providing exogenous UDP-GlcNAc 2-epimerase (e.g., neuC of Campylobacter jejuni (GenBank AAK91727.1; GL15193223)) or equivalent (e.g., neuC of E. coli S88 (GenBank YP_002392936.1; GI: 218560023)), Neu5Ac synthetase (e.g., neuB of Campylobacter jejuni (GenBank AAK91726.1; GI: 15193222)) or equivalent (e.g., Flavobacterium limnosediminis sialic acid synthase, GenBank GL559220424)) and / or CMP-Neu5Ac synthetase (e.g., neuA of Campylobacter jejuni (GenBank AAK91728.1; Gl: 15193224)) or an equivalent (e.g., Vibrio brasiliensis CMP-sialic acid synthetase, GenBank GI: 493937153)), the bacteria comprises sialic acid synthesis capability.
[0068] Production of fucosylated HMOs in engineered yeast is also known in the art (see, e.g., Yu et al., (2018) Microb Cell Fact 17:101; Hollands et al., (2019) Methabolic Eng 52:232-242)).
[0069] In order to produce HMOs containing N-acetylglucosamine, such as lacto-N-triose 2 (LNT-2), lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), lacto-N-fucopentaose I (LNFP-I), lacto-N-fucopentaose II (LNFP-II), lacto-N-fucopentaose III (LNFP-III), lacto-N-fucopentaose V (LNFP-V), lacto-N-difucohexaose I (LDFH-I), lacto-N-difucohexaose II (LDFH-II) and lacto-N-neodifucohexaose II (LNDFH-III), the bacteria include a functional lacY gene and a functionally abnormal lacZ gene, as described above, and are modified to include an exogenous UDP-GlcNAc:Galα / β-RN-acetylglucosaminyltransferase gene (GlcNAcT) or a functional variant or fragment thereof. The exogenous UDP-GlcNAc:Galα / β-R-3-N-acetylglucosaminyltransferase gene can be obtained from any of several sources (see Table 1), for example, the IgtA gene from Neisseria meningitidis (N. meningitidis) (Genbank protein accession number AAF42258.1) or Neisseria gonorrhoeae (N. gonorrhoeae) (Genbank protein accession number ACF31229.1). Optionally, additional exogenous glycosyltransferase genes are co-expressed in bacteria including the exogenous UDP-GlcNAc:Galα / β-R-3-N-acetylglucosaminyltransferase. For example, a β-1,4-galactosyltransferase gene (Gal4T) is co-expressed with a UDP-GlcNAc:Galα / β-R-3-N-acetylglucosaminyltransferase gene. The exogenous β-1,4-galactosyltransferase gene can be obtained from any of several sources, for example, the IgtB gene from Neisseria meningitidis (Genbank Protein Accession No. AAF42257.1), or the HP0826 / galT gene from Helicobacter pylori (H. pylori) (Genbank Protein Accession No. NP_207619.1).Optionally, the additional exogenous glycosyltransferase gene co-expressed in the bacterium including the exogenous UDP-GlcNAc:Galα / β-R-3-N-acetylglucosaminyltransferase gene is a β-1,3-galactosyltransferase gene (Gal3T), for example, the wbgO gene (Genbank protein accession number WP_000582563) from Escherichia coli 055:H7, or the jhp0563 gene (Genbank protein accession number AEZ55696.1) from Helicobacter pylori, or the cpsIBJ gene (Genbank protein accession number AB050723) from Streptococcus agalactiae type Ib OI2. Functional variants and fragments of any of the above enzymes are also included in the invention.
[0070] The gene of N-acetylglucosaminyltransferase and / or the gene of galactosyltransferase can also be operably linked to Pglp and expressed from the corresponding genome integration component. In one embodiment, the gene integrated into the genome is a gene encoding galactosyltransferase, such as the HP0826 gene encoding the GalT enzyme from Helicobacter pylori (Genbank protein accession number NP_207619.1); In another embodiment, the gene integrated into the genome is a gene encoding β-1,3-N-acetylglucosaminyltransferase, such as the IgtA gene from Neisseria meningitidis (Genbank protein accession number AAF42258.1). In these embodiments, the second gene, i.e., the gene encoding β-1,3-N-acetylglucosaminyltransferase or galactosyltransferase, can be expressed from the genome integrated or plasmid-carried component accordingly. The second gene can be optionally expressed under the control of the glp promoter or under the control of any other promoter suitable for the expression system, such as Plac.
[0071] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the invention belongs. Singleton et al. (1994) Dictionary of Microbiology and Molecular Biology, second edition, John Wiley and Sons (New York) provides a general dictionary of many of the terms used in the present invention for those skilled in the art. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, preferred methods and materials are described. Most of the nomenclature and general laboratory methods required for this application can be found in Sambrook et al., Molecular Cloning: A Laboratory Manual, Vol. 1-3, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (2012); Wilson K. and Walker J., Principles and Techniques of Biochemistry and Molecular Biology (2010), Cambridge University Press; or in Maniatise et al., Molecular Cloning A laboratory Manual, Cold Spring Harbor Laboratory (2012); or in Ausubel et al., Current protocols in molecular biology, John Wiley and Sohns (2010). These manuals are hereinafter referred to as "Sambrook et al.", "Wilson & Walker," "Maniatise et al.", "Ausubel et al.", respectively.
[0072] A second aspect of the present invention relates to a method for producing one or more HMOs, the method comprising the steps of:
[0073] (i) providing a genetically modified cell capable of producing HMO, wherein the cell comprises a recombinant nucleic acid encoding the protein of SEQ ID NO: 1 or a functional homologue thereof, the amino acid sequence of the functional homologue having at least 80% identity, preferably at least 85% identity, more preferably at least 90% identity to SEQ ID NO: 1;
[0074] (ii) culturing the cells of (i) in a suitable cell culture medium to allow the production of the HMO and the expression of the DNA sequence, thereby producing a protein having the amino acid sequence of SEQ ID NO: 1; or a functional homologue having an amino acid sequence of at least 80% identity, preferably at least 85% identity, more preferably at least 90% identity to SEQ ID NO: 1;
[0075] (iii) harvesting the HMO produced in step (ii).
[0076] According to the present invention, the term "cultivation" (or "culture" or "culturing", also called "fermentation") relates to the propagation of bacterial expression cells in a controlled bioreactor according to methods known in the industry.
[0077] To produce one or more HMOs, the bacteria producing HMOs as described herein are cultured in the presence of a suitable carbon source, such as glucose, glycerol, lactose, etc., according to methods known in the art, and the produced HMOs are harvested from the culture medium and the microbial biomass generated during the culture process. Thereafter, the HMOs are purified according to methods known in the art, such as those described in WO2015188834, WO2017182965 or WO2017152918, and the purified HMOs can be used as nutraceuticals, drugs, or for any other purpose, such as for research. The manufacture of HMOs is usually accomplished by culturing in larger quantities. The terms "manufacturing" and "manufacturing scale" in the present invention are defined as fermentation with a minimum volume of 5 L of culture broth. Generally, a "manufacturing scale" process is defined as being able to process a large amount of a preparation containing the HMO or multiple HMOs of interest, and, for example, in the case of a therapeutic compound or composition, being able to produce a yield of the protein of interest that meets clinical trials and market supply needs. Besides the large quantities, manufacturing-scale processes are also characterized by the use of bioreactor (fermenter) technology systems, equipped with means for stirring, aeration, nutrient supply, monitoring and control of process parameters (pH, temperature, dissolved oxygen tension, back pressure, etc.), compared to simple laboratory-scale processes such as shake flask cultivation. To a large extent, the behavior of the expression system in laboratory-scale processes, such as shake flasks, bench-top bioreactors or the deep well format described in the disclosed examples, does allow predicting how the system will behave in the complex environment of a bioreactor.
[0078] With regard to suitable cell culture media for use in the fermentation process, there are no restrictions. The culture medium may be semi-synthetic, i.e. contain complex culture media compounds (e.g. yeast extract, soy peptone, casein hydrolysate, etc.), or it may be chemically defined, without any complexing compounds.
[0079] The term "one or more HMOs" means that the HMO producing cell may be capable of producing a single HMO structure (a first HMO) or multiple HMO structures (a second HMO, a third HMO, etc.). In some embodiments, a host cell producing a single HMO may be preferred, and in other preferred embodiments, a host cell producing multiple HMO structures may be preferred. Non-limiting examples of host cells producing a single HMO structure are cells producing 2'-FL, 3-FL, 3'-SL, 6'-SL or LNT-2. Non-limiting examples of host cells capable of producing multiple HMO structures may be cells producing DFL, FSL, LNT, LNnT, LNFP I, LNFP II, LNFPIII, LNFP IV, LNFP V, pLNnH.
[0080] The term "harvest" in the context of the present invention refers to the collection of the produced HMOs after the fermentation is terminated. In different embodiments, it may include collecting the HMOs included in the biomass (i.e., host cells) and the culture medium, i.e., before / without separation of the fermentation broth from the biomass. In other embodiments, the produced HMOs may be separately from the biomass and the fermentation broth, i.e., after / after the separation of the biomass from the culture medium (i.e., the fermentation broth). The cells may be separated from the culture medium using any method known to those skilled in the art, such as any suitable type of centrifugation or filtration. The separation of cells from the culture medium may be performed immediately after the fermentation broth is harvested, or at a subsequent stage after the fermentation broth is stored under appropriate conditions. Recovering the generated HMOs from the remaining biomass (or total fermentation) includes extracting them from the biomass (i.e., production cells). It may be accomplished by any suitable method in the art, such as by ultrasonic treatment, boiling, homogenization, enzymatic lysis using lysozyme, or freezing and grinding.
[0081] After recovery from fermentation, HMOs can be used for further processing and purification.
[0082] Purification of HMOs produced by fermentation can be carried out using suitable methods described in WO2016095924, WO2015188834, WO2017152918, WO2017182965, US20190119314 (all incorporated by reference).
[0083] In some embodiments of the invention, the host cell can produce several HMOs, one of which is a "product" HMO, and some / all other HMOs are "byproduct" HMOs. Typically, the byproduct HMO is a precursor to the main HMO, or a product of further modification of the main HMO. In some embodiments, it may be desirable to produce a large amount of the product HMO and a small amount of the byproduct HMO. The cells and methods for HMO production described herein allow for the controlled production of HMO products with a well-defined HMO profile, for example, in one embodiment, in the HMO mixture produced, the product HMO is the dominant HMO compared to the other HMOs (i.e., the byproduct HMOs) of the mixture, i.e., the product HMO is produced in higher amounts than the other byproduct HMOs; in other embodiments, cells producing the same HMO mixture can be adjusted so that one or more byproduct HMOs are produced in higher amounts than the product HMO. For example, during the production of 3-FL (product HMO), a large amount of DFL (byproduct HMO) is typically produced. Using the genetically modified cells of the present invention, the level of DFL content in the 3-FL product can be significantly reduced.
[0084] Advantageously, the present invention reduces the ratio of byproducts to products while increasing the overall yield of products (and / or total HMOs). Thus, byproduct formation is reduced relative to product formation, favoring increased product formation and increasing the efficiency of the production and product recovery processes, thereby providing a superior HMO manufacturing process.
[0085] In different preferred embodiments, different host cells can be selected to produce one or both of 2'-FL, 3-FL, 3'-SL, 6'-SL, LNT-2, DFL, FSL, LNT, LNnT, DFL, FSL, LNT, LNnT, LNFP I, LNFP II, LNFP III, LNFPIV, LNFP V, and pLNnH as product or byproduct HMO. In a preferred embodiment, the product is 3-FL and the byproduct is DFL. In another preferred embodiment, the product is 2'-FL and the byproduct is DFL. In another preferred embodiment, the product is LNT-2 and the byproduct is LNT and LNFP I.
[0086] The present invention also relates to the use of the genetically modified cells and / or nucleic acid constructs according to the invention for producing one or more oligosaccharides, preferably one or more human milk oligosaccharides. In one embodiment, the genetically modified cells or nucleic acid constructs according to the invention are used for the production of a specific HMO selected from 2'-FL, 3-FL, DLF, LNT, LNT-II, LNnT, pLNnH and pLNH-II.
[0087] In a particularly preferred embodiment, the genetically modified cells and / or nucleic acid constructs according to the invention are used for the production of a specific HMO selected from 2'-FL and 3-FL.
[0088] The present invention is further illustrated by the following non-limiting examples and embodiments.
[0089] Example
[0090] Materials and methods
[0091] Unless otherwise indicated, standard techniques, vectors, control sequence elements and other expression system elements known in the field of molecular biology are used for nucleic acid manipulation, transformation and expression. Such standard techniques, vectors and elements can be found, for example: Ausubel et al. (eds.), Current Protocols in Molecular Biology (1995) (John Wiley & Sons); Sambrook, Fritsch, & Maniatis (eds.), Molecular Cloning (1989) (Cold Spring Harbor Laboratory Press, NY); Berger & Kimmel, Methods in Enzymology 152: Guide to Molecular Cloning Techniques (1987) (Academic Press); Bukhari et al. (eds.), DNA Insertion Elements, Plasmids and Episomes (1977) (Cold Spring Harbor Laboratory Press, NY); Miller, JH Experiments in molecular genetics (1972) (Cold spring Harbor Laboratory Press, NY).
[0092] The embodiments described below are intended to illustrate the present invention, but are not intended to limit the present invention in any way.
[0093] strains
[0094] The strain used was MDO, constructed from E. coli K12 DH1, the genotype of E. coli K12 DH1 was: Fˉ, gyrA96, recA1, relA1, endA1, thi-1, hsdR17, supE44. The strains used in this example are described in Table 2.
[0095] Table 2
[0096]
[0097] Culture medium
[0098] Luria Broth (LB) medium was prepared using LB broth powder, Millers (Fisher Scientific), and LB agar plates were prepared using LB agar powder, Millers (Fisher Scientific). Ampicillin ((100 μg / mL) or any suitable antibiotic) and / or chloramphenicol (20 μg / mL) were added as appropriate.
[0099] The basic minimal medium has the following composition: NaOH (1 g / L), KOH (2.5 g / L), KH2PO4 (7 g / L), NH4H2PO4 (7 g / L), citric acid (0.5 g / L), trace mineral solution (5 mL / L). The trace mineral stock solution contains: ZnSO4*7H2O 0.82 g / L, citric acid 20 g / L, MnSO4*H2O 0.98 g / L, FeSO4*7H2O 3.925 g / L, CuSO4*5H2O 0.2 g / L. The pH of the basic minimal medium is adjusted to 7.0 with 5N NaOH and autoclaved. Prior to inoculation, the basic minimal medium is provided with 1 mM MgSO4, 4 μg / mL thiamine, 0.5% of a given carbon source (glycerol (Carbosynth)). Thiamine and antibiotics are sterilized by filtration. All percentage concentrations of glycerol are expressed as v / v and percentage concentrations of glucose are expressed as w / v.
[0100] M9 plates containing 2-deoxygalactose had the following composition: 15 g / L agar (Fisher Scientific), 2.26 g / L 5x M9 Minimal Salt (Sigma-Aldrich), 2 mM MgSO4, 4 μg / mL thiamine, 0.2% glycerol, and 0.2% 2-deoxy-D-galactose (Carbosynth).
[0101] MacConkey indicator plates have the following composition: 40 g / L MacConkey agar base (BD Difco TM ) and a carbon source at a final concentration of 1%.
[0102] nourish
[0103] Unless otherwise stated, E. coli strains were propagated in Luria-Bertani (LB) medium containing 0.2% glucose at 37° C. with agitation. Agar plates were incubated at 37° C. overnight.
[0104] Chemically competent cells and transformation
[0105] At 37°C, E. coli was inoculated from an LB plate into 5 mL LB containing 0.2% glucose while shaking until OD 600-0.4. Centrifuged at 13.000 g for 25 seconds, 2 mL of culture was harvested. The supernatant was removed and the cell pellet was resuspended in 600 μL of cold TB solution (10 mM PIPES, 15 mM CaCl2, 250 mM KCl). The cells were incubated on ice for 20 minutes and then precipitated at 13.000 g for 15 seconds. The supernatant was removed and the cell pellet was resuspended in 100 μL of cold TB solution. Plasmid transformation was performed using 100 μL competent cells and 1-10 ng of plasmid DNA. The cells and DNA were incubated on ice for 20 minutes and then heat-shocked at 42°C for 45 seconds. After incubation on ice for 2 min, 400 μL SOC (20 g / L tryptone, 5 g / L yeast extract, 0.5 g / L NaCl, 0.186 g / L KCl, 10 mM MgCl2, 10 mM MgSO4, and 20 mM glucose) was added, and the cell culture was incubated with shaking at 37°C for 1 h before being plated on selective plates.
[0106] Plasmids were transformed into TOP10 chemically competent cells under conditions recommended by the supplier (ThermoFisher Scientific).
[0107] DNA Technology
[0108] Plasmid DNA from E. coli was isolated using the QIAprep Spin Miniprep Kit (Qiagen). Chromosomal DNA from E. coli was isolated using the QIAmp DNA Mini Kit (Qiagen). PCR products were purified using the QIAquick PCR Purification Kit (Qiagen). DreamTaq PCR Master Mix (Thermofisher), Phusion U hotstart PCR master mix (Thermofisher), and USER Enzym (New England Biolab) were used according to the supplier's recommendations. Primers were provided by Eurofins Genomics, Germany. PCR fragments and plasmids were sequenced by Eurofins Genomics. TMColony PCR was performed using DreamTaq PCR Master Mix in a thermal cycler (Bio-Rad).
[0109] Table 3: Oligos used to amplify plasmid backbones, promoter elements, and MARC
[0110]
[0111] Table 4: Heterologous proteins expressed in HMO production cells
[0112] Gene Gene source GenBank protein accession number Protein function futC Helicobacter pylori 26695 ABO61751.1 α-1,2-fucosyltransferase futA Helicobacter pylori 26695 NP_207177.1 α-1,3-fucosyltransferase marc Serratia marcescens WP_060448169.1 MFS transporter
[0113] Table 5: Synthetic DNA for MARC expression
[0114]
[0115]
[0116] Plasmid construction
[0117] Synthesize plasmid backbone, it contains two I-SceI nuclease sites, and the above two sites are separated by two DNA fragments and T1 transcription terminator sequences suitable for homologous recombination to Escherichia coli genome.For example, synthesize gal operon (needed for homologous recombination in galK) and T1 transcription terminator sequence (pUC57::gal) (GeneScript) in a plasmid backbone.The DNA sequence used for homologous recombination in the gal operon covers the base pairs 3.628.621-3.628.720 and 3.627.572-3.627.671 of the complete genome GenBank:ID:CP014225.1 sequence of Escherichia coli K-12MG155.Insert by homologous recombination can cause 949 base pairs of galK and galK-phenotype deletion. In a similar manner, a skeleton based on pUC57 (GeneScript) or any other suitable vector can be synthesized, the skeleton containing two I-SceI endonuclease sites, which are separated by two DNA fragments suitable for homologous recombination into the Escherichia coli genome and T1 transcription terminator sequences. Standard techniques known in the field of molecular biology are used to design amplification of specific DNA sequences of primers and Escherichia coli K-12DH1 chromosomal DNA. Such standard techniques, vectors and elements can be found in, for example: Ausubel et al. (eds.), Current Protocols in Molecular Biology (1995) (John Wiley & Sons); Sambrook, Fritsch, & Maniatis (eds.), Molecular Cloning (1989) (Cold Spring Harbor Laboratory Press, NY); Berger & Kimmel, Methods in Enzymology 152: Guide to Molecular Cloning Techniques (1987) (Academic Press); Bukhari et al. (eds.).
[0118] Using oligomers O261 and O262, chromosomal DNA obtained from E. coli DH1 was used to amplify a 300 bp DNA fragment containing the promoter PglpF (Table 3).
[0119] A 1.197 bp DNA fragment containing a codon-optimized version of the marc gene from Serratia marcescens was synthesized by GeneScript (Table 5). The marc gene was amplified by PCR using oligonucleotides O737 and O738 (Table 3).
[0120] All PCR fragments (plasmid backbone, promoter-containing elements and marc gene) are purified and the plasmid backbone, promoter element () and DNA fragment containing marc are assembled. The plasmid is cloned by standard USER cloning. Any standard DNA cloning technique can be used to clone in any appropriate plasmid. The plasmid is transformed into TOP10 cells and selected on LB plates containing 100 μg / mL ampicillin (or any suitable antibiotic) and 0.2% glucose. The constructed plasmid is purified and the promoter sequence and the 5' end of the marc gene are verified by DNA sequencing (MWG Eurofins Genomics). In this way, a gene assembly containing any promoter of interest connected to the marc gene is constructed.
[0121] Construction of strains
[0122] The bacterial strain MDO constructed by Escherichia coli K-12DH1 was used. The genotype of Escherichia coli K-12DH1 is: Fˉ, gyrA96, recA1, relA1, endA1, thi-1, hsdR17, supE44. In addition to the E. coli K-12DH1 genotype, MDO also has the following modifications: lacZ: 1.5 kbp deleted, lacA: 0.5 kbp deleted, nanKETA: 3.3 kbp deleted, melA: 0.9 kbp deleted, wcaJ: 0.5 kbp deleted, mdoH: 0.5 kbp deleted, and Plac promoter inserted upstream of the gmd gene.
[0123] Insertion of an expression assembly containing a promoter linked to the marc gene and to a T1 transcription terminator sequence was performed by Gene Gorging essentially as described by Herring et al. (Herring, CD, Glasner, JD and Blattner, FR (2003). Gene (311). 153-163). In brief, the donor plasmid and the helper plasmid were co-transformed into MDO and selected on LB plates containing 0.2% glucose, ampicillin (100 μg / mL) or kanamycin (50 mg / mL) and chloramphenicol (20 μg / mL). Single colonies were inoculated in 1 mL LB containing chloramphenicol (20 μg / mL) and 10 μL 20% L-arabinose and incubated at 37°C with shaking for 7-8 hours. To integrate into the galK locus of E. coli, cells were plated on M9-DOG plates and incubated at 37°C for 48 hours. The single colonies formed on the MM-DOG plate were re-streaked on LB plates containing 0.2% glucose and incubated at 37°C for 24 hours. Colonies that appeared white on MacConkey-galactose agar plates and were sensitive to both ampicillin and chloramphenicol were expected to have lost the donor and helper plasmids and contain inserts in the galK locus. Primers O48 and O49 (Table 3) were used to identify the insert in the galK locus by colony PCR, and the inserted DNA was verified by sequencing (Eurofins Genomics, Germany).
[0124] In a similar manner, insertion of the gene components is performed at other loci in the E. coli chromosomal DNA using different selectable marker genes.
[0125] Deep hole inspection (DWA)
[0126] DWA was performed as originally described by Lv et al. (Bioprocess Biosyst Eng (2016) 39: 1737-1747) and optimized for the purposes of the present invention. More specifically, the strains disclosed in the examples were screened in 24 deep well plates using a 4-day protocol. Within the first 24 hours, the cells grew to high density, and within the next 72 hours, the cells were transferred to a culture medium that allowed induction of gene expression and product formation. Specifically, on day 1, a fresh inoculum was prepared using a basic minimal medium supplemented with magnesium sulfate, thiamine, and glucose. After the prepared culture was incubated at 34°C with shaking at 700rpm for 24 hours, the cells were transferred to a new basic minimal medium (2ml) supplemented with magnesium sulfate and thiamine, to which an initial 20% glucose solution (1μl) and 10% lactose solution (0.1ml) were added, and then 50% sucrose solution was provided to the cells as a carbon source. After inoculation of the new culture medium, the cells were shaken at 700rpm at 28°C for 72 hours. After denaturation and subsequent centrifugation, the supernatant was analyzed by HPLC.
[0127] For analysis of total samples, cell lysates prepared by boiling were pelleted by centrifugation at 4700 rpm for 10 minutes. The HMO concentration in the supernatant was determined by HPLC or HPAC methods.
[0128] result
[0129] Example 1. Engineering of E. coli expressing the marc gene for 3-FL production
[0130] E. coli K-12 (DH1) MDO strains can be manipulated to express heterologous genes of interest. For example, strain MPA5 is a 3-FL production strain that overexpresses the α-1,3-fucosyltransferase gene, futA, and the colic acid gene (gmd-fcl-gmm-wcal-cpsB-cpsG). An expression assembly containing a promoter element (PglpF) linked to the marc gene was inserted in a single copy into the MPA5 background strain to produce strain MPA6 and result in i) relatively high amounts of 3-FL in the culture medium and ii) relatively low amounts of 3-FL inside the cells ( Figure 1 ).
[0131] Example 2. Engineering of E. coli expressing the marc gene for 2'-FL production
[0132] E. coli K-12 (DH1) MDO strains can be manipulated to express heterologous genes of interest. For example, strain MPA1 is a 2'-FL production strain that overexpresses the α-1,2-fucosyltransferase gene, futC, and the colic acid gene (gmd-fcl-gmm-wcal-cpsB-cpsG). An expression assembly containing a promoter element (PglpF) linked to the marc gene was inserted into MPA1 chromosomal DNA to generate strain MPA7, and resulted in i) a relatively high amount of 2'-FL in the culture medium, and ii) a relatively low amount of 2'-FL inside the cells ( Figure 2A ), and iii) a relatively low optical density at 600 nm ( Figure 2B ). Sequence Listing <110> Gleikam AG <120> HMO Production <130> P2938WO00 <150> DK202000086 <151> 2020-01-23 <160> 14 <170> BiSSAP 1.3.6 <210> 1 <211> 398 <212> PRT <213> Serratia marcescens <220> <223> Marc WP_060448169.1\Optimized translation <400> 1 Met Gln Arg Leu Ser Arg Leu Ser Leu Arg Ile Asn Pro Ile Phe Ala 1 5 10 15 Ala Phe Leu Leu Ile Ala Phe Leu Ser Gly Ile Ala Gly Ala Leu Leu 20 25 30 Thr Pro Thr Leu Ser Leu Phe Leu Thr Thr Glu Val Lys Val Arg Pro 35 40 45 Leu Trp Val Gly Leu Phe Tyr Thr Ala Asn Ala Val Ala Gly Ile Val 50 55 60 Val Ser Phe Leu Leu Ala Lys Arg Ser Asp Thr Arg Gly Asp Arg Arg 65 70 75 80 Arg Leu Ile Leu Leu Cys Cys Leu Met Ala Val Gly Asn Cys Leu Leu 85 90 95 Phe Ala Phe Asn Arg Asp Tyr Leu Thr Leu Ile Thr Ala Gly Val Leu 100 105 110 Met Ser Ala Val Ala Asn Thr Ala Met Pro Gln Ile Phe Ala Leu Ala 115 120 125 Arg Glu Tyr Ala Asp Ser Glu Ala Arg Glu Val Val Met Phe Ser Ser 130 135 140 Val Met Arg Ala Gln Leu Ser Leu Ala Trp Val Ile Gly Pro Pro Leu 145 150 155 160 Ser Phe Ala Leu Ala Leu Asn Tyr Gly Phe Thr Val Met Phe Leu Ile 165 170 175 Ala Ala Val Thr Phe Ala Val Cys Val Leu Leu Val Gly Phe Met Leu 180 185 190 Pro Ser Val Pro Arg Ala Ala Glu Asn Glu Gly Leu Gln Gly Gly Val 195 200 205 Ser Ala Pro Ile Ala Pro Ala Ser Ala Trp Arg Asn Arg Asp Val Arg 210 215 220 Leu Leu Phe Ile Ala Ser Met Leu Met Trp Thr Cys Asn Thr Leu Tyr 225 230 235 240 Ile Ile Asp Met Pro Leu Tyr Ile Thr Ala Asp Leu Gly Leu Pro Glu 245 250 255 Gly Leu Ala Gly Val Leu Met Gly Thr Ala Ala Gly Leu Glu Ile Pro 260 265 270 Ala Met Leu Leu Ala Gly Tyr Tyr Val Lys Arg Phe Gly Lys Arg Asn 275 280 285 Met Met Leu Leu Ala Val Val Ala Gly Val Leu Phe Tyr Leu Gly Leu 290 295 300 Thr Val Leu Glu Ser Lys Pro Ala Leu Ile Ala Leu Gln Leu Leu Asn 305 310 315 320 Ala Val Phe Ile Gly Ile Val Ala Gly Ile Gly Met Leu Tyr Phe Gln 325 330 335 Asp Leu Met Pro Gly Arg Pro Gly Ala Ala Thr Thr Leu Phe Thr Asn 340 345 350 Ser Ile Ser Thr Gly Val Ile Leu Ala Gly Val Leu Gln Gly Ala Leu 355 360 365 Val Glu Asn Leu Gly His Gly Ser Val Tyr Trp Met Ala Ala Leu Leu 370 375 380 Ala Leu Ala Ala Leu Gly Met Ser Ala Lys Val Arg Glu Val 385 390 395 <210> 2 <211> 1197 <212> DNA <213> Serratia marcescens <220> <223> marc nucleotide sequence <400> 2 atgcagcgtc tgagccgtct gagcctgcgt atcaacccga ttttcgcggc gtttctgctg 60 atcgcgttcc tgagcggtat tgcgggtgcg ctgctgaccc cgaccctgag cctgtttctg 120 accaccgagg tgaaggttcg tccgctgtgg gtgggtctgt tctacaccgc gaacgcggtt 180 gcgggcatcg tggttagctt tctgctggcg aaacgtagcg acacccgtgg tgaccgtcgt 240 cgtctgattc tgctgtgctg cctgatggcg gtgggcaact gcctgctgtt cgcgtttaac 300 cgtgactacc tgaccctgat caccgcgggt gtgctgatga gcgcggttgc gaacaccgcg 360 atgccgcaga ttttcgcgct ggcgcgtgaa tatgcggata gcgaggcgcg tgaagtggtt 420 atgtttagca gcgtgatgcg tgcgcaactg agcctggcgt gggttattgg tccgccgctg 480 agcttcgcgc tggcgctgaa ctatggcttc accgtgatgt ttctgattgc ggcggttacc 540 ttcgcggtgt gcgttctgct ggttggtttt atgctgccga gcgttccgcg tgcggcggag 600 aacgaaggcc tgcagggtgg cgtgagcgcg ccgattgcgc cggcgagcgc gtggcgtaac 660 cgtgacgttc gtctgctgtt tattgcgagc atgctgatgt ggacctgcaa caccctgtac 720 atcattgaca tgccgctgta tatcaccgcg gatctgggtc tgccggaggg tctggcgggc 780 gtgctgatgg gcaccgcggc gggcctggaa atcccggcga tgctgctggc gggttactat 840 gttaagcgtt tcggcaaacg taacatgatg ctgctggcgg tggttgcggg tgtgctgttt 900 tacctgggcc tgaccgttct ggagagcaaa ccggcgctga ttgcgctgca gctgctgaac 960 gcggtgttca tcggtattgt tgcgggtatt ggcatgctgt attttcagga cctgatgccg 1020 ggtcgtccgg gtgcggcgac caccctgttc accaacagca tcagcaccgg cgtgattctg 1080 gcgggtgttc tgcaaggcgc gctggttgag aacctgggtc acggcagcgt ttactggatg 1140 gcggcgctgc tggcgctggc ggcgctgggt atgagcgcga aagtgcgtga agtttaa 1197 <210> 3 <211> 300 <212> DNA <213> Artificial sequence <220> <223> PglpF expression element <300> <310> WO2019123324 <311> 19.12.2018 <312> 27.06.2019 <400> 3 gcggcacgcc ttgcagatta cggtttgcca cacttttcat ccttctcctg gtgacataat 60 ccacatcaat cgaaaatgtt aataaatttg ttgcgcgaat gatctaacaa acatgcatca 120 tgtacaatca gatggaataa atggcgcgat aacgctcatt ttatgacgag gcacacacat 180 tttaagttcg atatttctcg tttttgctcg ttaacgataa gtttacagca tgcctacaag 240 catcgtggag gtccgtgact ttcacgcata caacaaacat taaccaagga ggaaacagct 300 <210> 4 <211> 34 <212> DNA <213> Artificial sequence <220> <223> Primer O40 backbone.for <220> <221> misc_RNA <222> 9 <400> 4 attaacccuc caggcatcaa ataaaacgaa aggc 34 <210> 5 <211> 32 <212> DNA <213> Artificial sequence <220> <223> Primer O79 Backbone.rev <220> <221> misc_RNA <222> 10 <400> 5 atttgcgcau caccaatcaa attcacgcgg cc 32 <210> 6 <211> 32 <212> DNA <213> Artificial sequence <220> <223> Primers O261, PglpF.for <220> <221> misc_RNA <222> 10 <400> 6 atgcgcaaau gcggcacgcc ttgcagatta cg 32 <210> 7 <211> 36 <212> DNA <213> Artificial sequence <220> <223> Primers O262, PglpF.rev <220> <221> misc_RNA <222> 8 <400> 7 agctgttucc tccttggtta atgtttgttg tatgcg 36 <210> 8 <211> 31 <212> DNA <213> Artificial sequence <220> <223> Primer O737, marc.for <220> <221> misc_RNA <222> 8 <400> 8 aaacagcuat gcagcgtctg agccgtctga g 31 <210> 9 <211> 32 <212> DNA <213> Artificial sequence <220> <223> Primer O738, marc.rev <220> <221> misc_RNA <222> 9 <400> 9 agggttaaut taaacttcac gcactttcgc gc 32 <210> 10 <211> twenty four <212> DNA <213> Artificial sequence <220> <223> Primer O48, galK.for <400> 10 cccagcgaga cctgaccgca gaac 24 <210> 11 <211> twenty four <212> DNA <213> Artificial sequence <220> <223> Primer O49, glaK.rev <400> 11 ccccagtcca tcagcgtgac tacc 24 <210> 12 <211> 203 <212> DNA <213> Artificial sequence <220> <223> Promoter sequence Pmg1B_70UTR <400> 12 tgcgtcgcca ttctgtcgca acacgccaga atgcggcggc gatcactaac tcaacaaatc 60 aggcgatgta accgctttca atctgtgagt gatttcacag tatcttaaca atgtgatagc 120 tatgattgca ccgtgcctac aagcatcgtg gaggtccgtg actttcacgc atacaacaaa 180 cattaaccaa ggaggaaaca gct 203 <210> 13 <211> 203 <212> DNA <213> Artificial sequence <220> <223> Promoter sequence Pmg1B_70UTR_SD4 <400> 13 tgcgtcgcca ttctgtcgca acacgccaga atgcggcggc gatcactaac tcaacaaatc 60 aggcgatgta accgctttca atctgtgagt gatttcacag tatcttaaca atgtgatagc 120 tatgattgca ccgtgcctac aagcatcgtg gaggtccgtg actttcacgc atacaacaaa 180 cattaaccaa ctaggaaaca gct 203 <210> 14 <211> 291 <212> DNA <213> Artificial sequence <220> <223> Promoter sequence PgatY_70UTR <400> 14 cggcaaccta tgcctgatgc gacgctgaag cgtctttatca tgcctacata gcactgccac 60 gtatgtttac accgcatccg gcataaaaac acgcgcactt tgctacggct tccctatcgg 120 gaggccgttt ttttgccttt cactcctcga atattttca tattgtcgtt tttgtgatcg 180 240. ttatctcgat atttaaaaac aaataatttc attatatttt gtgcctacaa gcatcgtgga ggtccgtgac tttcacgcat acaacaaaca ttaaccaagg aggaacagc t
Claims
1. A genetically modified cell capable of producing one or more human milk oligosaccharides (HMOs), wherein the cell comprises a recombinant nucleic acid encoding the protein of SEQ ID NO: 1, and the HMOs are selected from 2'-fucosyllactose (2'-FL), 3-fucosyllactose (3-FL) and 6'-sialyllactose (6'-SL), and The genetically modified cell further comprises at least one recombinant nucleic acid encoding an enzyme having glycosyltransferase activity, wherein the enzyme having glycosyltransferase activity is selected from α-1,2-fucosyltransferase, α-1,3-fucosyltransferase and α-2,6-sialyltransferase.
2. The genetically modified cell of claim 1, wherein the genetically modified cell is Escherichia coli.
3. The genetically modified cell according to claim 1 or 2, wherein the cell further comprises a recombination regulatory element, wherein the recombination regulatory element comprises a nucleic acid sequence for regulating the expression of the recombinant nucleic acid.
4. The genetically modified cell according to claim 3, wherein the regulatory element for regulating the expression of the recombinant nucleic acid comprises a lac promoter Plac, or a glp promoter PglpF.
5. A use of a nucleic acid construct for producing one or more human milk oligosaccharides (HMOs), the nucleic acid construct comprising a protein encoding SEQ ID NO: 1, wherein the nucleic acid sequence encoding the protein of SEQ ID NO: 1 has at least 99% sequence identity with SEQ ID NO: 2, and the HMO is selected from 2'-fucosyllactose (2'-FL), 3-fucosyllactose (3-FL) and 6'-sialyllactose (6'-SL), and The nucleic acid construct further comprises at least one recombinant nucleic acid encoding an enzyme having glycosyltransferase activity, wherein the enzyme having glycosyltransferase activity is selected from α-1,2-fucosyltransferase, α-1,3-fucosyltransferase and α-2,6-sialyltransferase.
6. The use according to claim 5, wherein the construct further comprises a nucleic acid sequence having a regulatory element.
7. The use according to claim 6, wherein the regulatory element regulates the expression of a nucleic acid sequence having at least 99% sequence identity with SEQ ID NO:
2.
8. The use according to claim 6 or 7, wherein the regulatory element for regulating the expression of the nucleic acid sequence is the lac promoter Plac, or the glp promoter PglpF.
9. A method for producing one or more human milk oligosaccharides (HMOs), the method comprising the steps of: (i) providing a genetically modified cell capable of producing an HMO, wherein the cell comprises a recombinant nucleic acid encoding the protein of SEQ ID NO: 1; (ii) culturing the cell according to (i) in a suitable cell culture medium to express the recombinant nucleic acid, or a functional homologue thereof; (iii) harvesting the one or more HMOs produced in step (ii), wherein the HMO is selected from 2'-fucosyllactose (2'-FL), 3-fucosyllactose (3-FL) and 6'-sialyllactose (6'-SL), and The genetically modified cell further comprises at least one recombinant nucleic acid encoding an enzyme having glycosyltransferase activity, wherein the enzyme having glycosyltransferase activity is selected from α-1,2-fucosyltransferase, α-1,3-fucosyltransferase and α-2,6-sialyltransferase.
10. Use of the genetically modified cell according to any one of claims 1 to 4 for producing one or more human milk oligosaccharides (HMOs), wherein the HMOs are selected from 2'-fucosyllactose (2'-FL), 3-fucosyllactose (3-FL) and 6'-sialyllactose (6'-SL).
